Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al
I drafted an entire paper over the course of a week, including collecting and processing 75% of the data that I needed
Compared with metformin and second- or third-line glucose-lowering medication groups, major adverse CVEs were significantly lower in patients with NAFLD and type 2 diabetes taking GLP-1RAs, but not different from those taking SGLT2 inhibitors
The platform may be worth evaluating for adults who: Prefer a fully online intake, provider review, and home delivery process for eligible prescription programs Are researching GLP-1-supported weight management and want a platform that names its physicians and pharmacy partners publicly Want FSA/HSA-eligible telehealth access across multiple health categories in a single platform Are members of or allies within the LGBTQ+ community and want care from a platform built with that community's needs as the primary design consideration Need Spanish-speaking provider availability Are comfortable with the no-refund structure and auto-renewal terms described above CareBareRX may not be the right fit for people who require in-person medical evaluation, have contraindications to the medications being considered (see safety disclosures above), need insurance to cover prescription costs, want a refund option if a prescription is not approved, or are not comfortable with auto-renewal billing and final-sale prescription terms
%203_2.webp?width=1600&height=1067&name=Onglyza%20(saxagliptin)%203_2.webp)
